142 related articles for article (PubMed ID: 14966921)
1. Levels of v5 and v6 CD44 splice variants in serum of patients with colorectal cancer are not correlated with pT stage, histopathological grade of malignancy and clinical features.
Zalewski B
World J Gastroenterol; 2004 Feb; 10(4):583-5. PubMed ID: 14966921
[TBL] [Abstract][Full Text] [Related]
2. Soluble CD44 v5 and v6 in serum of patients with breast cancer. Correlation with expression of CD44 v5 and v6 variants in primary tumors and location of distant metastasis.
Lackner C; Moser R; Bauernhofer T; Wilders-Truschnig M; Samonigg H; Berghold A; Zatloukal K
Breast Cancer Res Treat; 1998 Jan; 47(1):29-40. PubMed ID: 9493973
[TBL] [Abstract][Full Text] [Related]
3. Serum assay of soluble CD44 standard (sCD44-st), CD44 splice variant v5 (sCD44-v5), and CD44 splice variant v6 (sCD44-v6) in patients with epithelial ovarian cancer.
Gadducci A; Ferdeghini M; Fanucchi A; Annicchiarico C; Cosio S; Prontera C; Bianchi R; Genazzani AR
Anticancer Res; 1997; 17(6D):4463-6. PubMed ID: 9494551
[TBL] [Abstract][Full Text] [Related]
4. Characteristics of CD44 alternative splice pattern in the course of human colorectal adenocarcinoma progression.
Bánky B; Rásó-Barnett L; Barbai T; Tímár J; Becságh P; Rásó E
Mol Cancer; 2012 Nov; 11():83. PubMed ID: 23151220
[TBL] [Abstract][Full Text] [Related]
5. Prognostic value of CD44 splice variants in human stage III cervical cancer.
Kainz C; Kohlberger P; Tempfer C; Sliutz G; Gitsch G; Reinthaller A; Breitenecker G
Eur J Cancer; 1995 Sep; 31A(10):1706-9. PubMed ID: 7488429
[TBL] [Abstract][Full Text] [Related]
6. Soluble CD44 splice variants and pelvic lymph node metastasis in ovarian cancer patients.
Stickeler E; Vogl FD; Denkinger T; Mobus VJ; Kreienberg R; Runnebaum IB
Int J Mol Med; 2000 Nov; 6(5):595-601. PubMed ID: 11029531
[TBL] [Abstract][Full Text] [Related]
7. Serum CD44 splice variants in cervical cancer patients.
Kainz C; Tempfer C; Winkler S; Sliutz G; Koelbl H; Reinthaller A
Cancer Lett; 1995 Apr; 90(2):231-4. PubMed ID: 7537626
[TBL] [Abstract][Full Text] [Related]
8. Soluble CD44 splice variants in metastasizing human breast cancer.
Martin S; Jansen F; Bokelmann J; Kolb H
Int J Cancer; 1997 Aug; 74(4):443-5. PubMed ID: 9291436
[TBL] [Abstract][Full Text] [Related]
9. Isoform expression of CD44 adhesion molecules, Bcl-2, p53 and Ki-67 proteins in lung cancer.
Mizera-Nyczak E; Dyszkiewicz W; Heider KH; Zeromski J
Tumour Biol; 2001; 22(1):45-53. PubMed ID: 11054026
[TBL] [Abstract][Full Text] [Related]
10. [Expression of CD44 and isoforms v4, v5, v6, v7, v10--new prognostic parameters in ductal pancreatic carcinoma?].
Böttger T; Maschek H; Gottwald W; Lobo M; Brenner W; Junginger T
Chirurg; 1998 Oct; 69(10):1089-92. PubMed ID: 9833191
[TBL] [Abstract][Full Text] [Related]
11. Soluble CD44 molecules in serum of patients with prostate cancer and benign prostatic hyperplasia.
Jung K; Lein M; Weiss S; Schnorr D; Henke W; Loening S
Eur J Cancer; 1996 Apr; 32A(4):627-30. PubMed ID: 8695265
[TBL] [Abstract][Full Text] [Related]
12. Soluble CD44 isoforms in serum as potential markers of metastatic gastric carcinoma.
Harn HJ; Ho LI; Shyu RY; Yuan JS; Lin FG; Young TH; Liu CA; Tang HS; Lee WH
J Clin Gastroenterol; 1996 Mar; 22(2):107-10. PubMed ID: 8742647
[TBL] [Abstract][Full Text] [Related]
13. Serum CD44 levels in patients with non-small cell lung cancer and their relationship with clinicopathological features.
Takigawa N; Segawa Y; Mandai K; Takata I; Fujimoto N
Lung Cancer; 1997 Oct; 18(2):147-57. PubMed ID: 9316006
[TBL] [Abstract][Full Text] [Related]
14. The serum assay of soluble CD44 standard (sCD44-st), CD44 splice variant 5 (sCD44-v5), and CD44 splice variant 6 (sCD44-v6) in patients with cervical cancer.
Gadducci A; Ferdeghini M; Cosio S; Annicchiarico C; Fanucchi A; Prontera C; Bianchi R; Genazzani AR
Anticancer Res; 1998; 18(1B):537-9. PubMed ID: 9568174
[TBL] [Abstract][Full Text] [Related]
15. High serum levels of soluble CD44 variant isoform v5 are associated with favourable clinical outcome in ovarian cancer.
Zeimet AG; Widschwendter M; Uhl-Steidl M; Müller-Holzner E; Daxenbichler G; Marth C; Dapunt O
Br J Cancer; 1997; 76(12):1646-51. PubMed ID: 9413956
[TBL] [Abstract][Full Text] [Related]
16. Soluble CD44 variants in the serum of patients with urological malignancies.
Lein M; Jung K; Weiss S; Schnorr D; Loening SA
Oncology; 1997; 54(3):226-30. PubMed ID: 9143404
[TBL] [Abstract][Full Text] [Related]
17. CD44 splice variants as prognostic markers in colorectal cancer.
Wielenga VJ; van der Voort R; Mulder JW; Kruyt PM; Weidema WF; Oosting J; Seldenrijk CA; van Krimpen C; Offerhaus GJ; Pals ST
Scand J Gastroenterol; 1998 Jan; 33(1):82-7. PubMed ID: 9489913
[TBL] [Abstract][Full Text] [Related]
18. Increased serum levels of soluble CD44 standard, but not of variant isoforms v5 and v6, in B cell chronic lymphocytic leukemia.
De Rossi G; Marroni P; Paganuzzi M; Mauro FR; Tenca C; Zarcone D; Velardi A; Molica S; Grossi CE
Leukemia; 1997 Jan; 11(1):134-41. PubMed ID: 9001429
[TBL] [Abstract][Full Text] [Related]
19. Expression of CD44 splice variants during lymphocyte activation and tumor progression.
Griffioen AW; Horst E; Heider KH; Wielenga VJ; Adolf GR; Herrlich P; Pals ST
Cell Adhes Commun; 1994 Jul; 2(3):195-200. PubMed ID: 7530151
[TBL] [Abstract][Full Text] [Related]
20. Soluble CD44 variant 6 as a prognostic indicator in patients with colorectal cancer.
Yamane N; Tsujitani S; Makino M; Maeta M; Kaibara N
Oncology; 1999 Apr; 56(3):232-8. PubMed ID: 10202279
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
